Article

Genenta Science S.p.A. is undergoing a strategic transformation to become Saentra Forge S.p.A., targeting acquisitions in national-security sectors under Italian Golden Power legislation. The company aims for majority ownership in profitable businesses generating up to €5 million in EBITDA.

The first integration is with ATC, a defense-sector company. Praexidia Foundation joins as a long-term shareholder, enhancing governance and supporting acquisition strategies. The company has achieved clinical milestones to advance its cell therapy platform and is engaging with pharmaceutical partners to enhance market access.

As of December 31, 2025, cash and marketable securities are expected to be approximately $33 million, an increase from $17.7 million in June 2025, attributed to a direct offering. Shareholder approval for the name change and new Nasdaq ticker SAEN is scheduled for March 25-26, 2026.